04.04.2024, Geneva – In a significant step forward for personalized cancer care, Novigenix, a pioneer in AI healthcare solutions, has been selected as a key partner by the IMMUcan consortium for the development of RNA sequencing biomarkers and to advance the understanding of the immune system’s response to checkpoint inhibitors in cancer patients. IMMUcan consortium aims to advance cancer research by collaboratively profiling tumors and their microenvironments, generating insights into the interaction between the immune system and cancer, further contributing to the global fight against cancer. Against this backdrop, the collaboration between Novigenix and IMMUcan holds immense potential to improve patient outcomes and revolutionize the field of immuno-oncology. Dr. Pedro Romero, Chief Medical & Scientific Officer at Novigenix, stated, “Joining forces with the IMMUcan consortium represents a remarkable opportunity to harness the power of AI and next-generation RNA sequencing in decoding the complexities of the immune-tumor interaction for the benefit of cancer patients globally. By integrating our LITOseek™ platform, we aim to propel the development of robust RNA biomarkers, ultimately enhancing patient stratification and monitoring during immunotherapy.”
Novigenix joins forces with IMMUcan
Novigenix was formally integrated as a member of the IMMUcan consortium in February 2024. Leveraging its cutting-edge Liquid Biopsy Immuno-transcriptomics platform, LITOseek™, Novigenix is set to significantly enhance the immune profiling capabilities of the consortium. This strategic collaboration aims to uncover previously unknown insights into patients undergoing immunotherapies. Sabine Tejpar, Founder of IMMUcan Consortium, Head of Digestive Oncology, KU Leuven, and Associate Professor of KU Leuven Faculty of Medicine, echoes this sentiment: “The addition of Novigenix’s expertise and technology significantly enhances our ability to dissect the intricate mechanisms of the immune response to checkpoint inhibitors. This collaboration has the potential to revolutionize how we approach cancer treatment and ultimately improve the lives of patients worldwide.” As Novigenix and IMMUcan embark on this collaborative journey, their shared vision is poised to reshape the landscape of cancer care, providing hope and groundbreaking insights for patients and healthcare professionals and industry alike.
About Novigenix
Novigenix pioneers AI-driven healthcare solutions, analyzing RNA data to personalize cancer treatments and improve patient outcomes. Leveraging molecular technologies and AI, Novigenix maps systemic immune responses, facilitating tailored therapeutic advancements based on individual immune response profiles.
For over a decade, Novigenix has demonstrated leadership in bringing precision immunology to the market, integrating multi-omics data with AI through its proprietary LITOSeek™ platform. This innovative approach offers insights into patient immune responses, driving precision therapy developments.
About IMMUcan
The IMMUcan consortium stands at the forefront of collaborative efforts, representing a unique alliance comprising academic, patient organisation, and industry partners, under the leadership of Merck and EORTC.
The consortium aims to generate Real World Evidence for better understanding of the interaction
between the immune system and tumors, and the impact of therapeutic interventions by performing molecular and cellular profiling of cancer patients. In the longer term, the project results could aid in the identification of biological markers that will show which patients are most likely to respond well to immune therapies, and which patients would benefit from a combination of immune therapies and conventional treatments.
IMMUcan receives support from the European Union (grant 821558) within the Innovative Medicine Initiative 2 program (now known as Innovative Health Initiative) and from the European Federation of Pharmaceutical Industries.
